Technical Analysis for AGE - AgeX Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 3.8 25.00% 0.76
AGE closed up 25.0 percent on Thursday, December 13, 2018, on 23 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical AGE trend table...

Date Alert Name Type % Chg
Dec 13 Hot IPO Pullback Bullish Swing Setup 0.00%
Dec 13 Outside Day Range Expansion 0.00%
Dec 12 Hot IPO Pullback Bullish Swing Setup 25.00%
Dec 12 Down 3 Days in a Row Weakness 25.00%
Dec 11 Hot IPO Pullback Bullish Swing Setup 17.65%
Dec 10 Gapped Down Weakness -1.55%
Dec 6 Inside Day Range Contraction -26.21%
Dec 4 Inside Day Range Contraction -28.30%

Older signals for AGE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Is AGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.95
52 Week Low 1.13
Average Volume 438,895
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 4.315
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.23
Resistance 3 (R3) 5.12 4.53 4.99
Resistance 2 (R2) 4.53 4.17 4.59 4.91
Resistance 1 (R1) 4.17 3.95 4.35 4.28 4.83
Pivot Point 3.58 3.58 3.68 3.64 3.58
Support 1 (S1) 3.22 3.22 3.40 3.33 2.77
Support 2 (S2) 2.63 3.00 2.69 2.69
Support 3 (S3) 2.27 2.63 2.61
Support 4 (S4) 2.38